GLENMARKGlenmark Pharmaceuticals Ltd.

    Glenmark Pharmaceuticals Ltd: results and news

    Every Glenmark Pharmaceuticals Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings.

    1 article · Pharmaceuticals · Latest 5 Nov 2026

    A technician in a white coat working at laboratory glassware, in an old black-and-white photograph

    GLENMARKGlenmark Pharmaceuticals Ltd.

    Glenmark Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹264 Crore on Total Income of ₹4,250 Crore

    Glenmark Pharmaceuticals (NSE: GLENMARK) reported consolidated total income of ₹4,249.87 crore and consolidated net profit of ₹263.83 crore for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. Standalone total income was ₹2,584.01 crore and standalone net profit was ₹434.89 crore.

    • Earnings
    • Pharmaceuticals

    Blacklitt Research3 min read